Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lung cancer? early trial tests novel drug combo

NCT ID NCT06931626

Recruiting now Disease control Sponsor: Nerviano Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new oral drug called NMS-03305293, combined with the chemotherapy temozolomide, in 10 people with relapsed small cell lung cancer. The main goal is to check safety and tolerability, while also looking for signs that the tumors shrink. All participants have already tried standard treatments and have limited options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
NMS-03305293 (a new PARP inhibitor drug) combined with temozolomide (a chemotherapy drug)
What this could lead to
If it works, this could point toward a new treatment option for people with relapsed small cell lung cancer who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 10 participants, so it is primarily testing safety, not effectiveness. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • OSF Saint Francis Medical Center

    RECRUITING

    Peoria, Illinois, 61637, United States

  • Tennessee Oncology, PLLC

    RECRUITING

    Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.